Western blot results showed that the expression levels of p-AKT and p-ERK5 in Adriamycin-treated breast cancer cells were lower after FPRL2 knockdown, in both MCF-7 and MCF-7/ADM (Figure 7). This evidence concerns the gene FPR3 and breast cancer.